Ratings by Atlantic Equities (Steve Chesney)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/2/2023 | IDEXX Laboratories | IDXX | Downgrade | Neutral (Overweight) |
532.30 (562.20) |
5.62% | Details | |
| 5/2/2023 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2023 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/1/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/1/2022 | Abbvie | ABBV | Downgrade | Neutral (Overweight) |
149.75 (265.97) |
77.61% | Details | |
| 5/6/2022 | Zoetis Inc. | ZTS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2022 | Eli Lilly | LLY | Maintain | Neutral (N/A) |
|
Details | ||
| 5/3/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 6/8/2021 | Biogen | BIIB | New Coverage | Neutral (N/A) |
395.85 (221.56) |
-44.03% | Details | |
| 4/28/2021 | Amgen | AMGN | Downgrade | Underweight (Neutral) |
255.13 (442.36) |
73.39% | Details | |
| 11/9/2020 | Biogen | BIIB | Downgrade | Underweight (Neutral) |
328.90 (221.56) |
-32.64% | Details | |
| 9/21/2020 | Zoetis Inc. | ZTS | New Coverage | Overweight (N/A) |
160.47 (76.68) |
-52.22% | Details | |
| 6/23/2020 | Abbvie | ABBV | Upgrade | Overweight (Neutral) |
96.71 (265.97) |
175.02% | Details | |
| 8/14/2019 | Bristol-Myers Squibb Co. | BMY | Upgrade | Overweight (Neutral) |
46.51 (67.61) |
45.37% | Details | |
| 5/13/2019 | Merck | MRK | Upgrade | Overweight (Neutral) |
78.33 (152.20) |
94.31% | Details | |
| 4/1/2019 | Celgene | CELG | Downgrade | Neutral (Overweight) |
94.34 (108.24) |
14.73% | Details |
